Validation, workflow integration and the evidence needed to assess AI applications in biotech.
Merck–Moderna’s collaboration provides the timeline; a separate cash model tests option exercise, delay, settlement and the no-payment branch.
A patient-pathway funnel, starter-dose capacity check and financial threshold show why convenient dosing still needs an operating system.
Vyxeos provides the clinical anchor; a separate yield and cash-cost model tests whether a manufacturing improvement deserves investment.
FDA’s 2026 terminology change, a historical liver-chip benchmark and a transparent error-cost model show what a validation investment must establish.
AI can widen the search for a medicine. The more interesting question is how scientists decide which possibilities deserve to become experiments.
Define the baseline, deliverables and economic perspective before attributing time or money saved to an intervention.
Turn a leadership directory into a dated, evidence-based partnering process with measurable progression.
Historical financing events and a runway model clarify what a capital headline can—and cannot—tell a reader.
A decision framework for separating clinical evidence, regulatory credibility and usable economic returns.
The 2023 decision puts a measurable boundary around a broad molecular-platform narrative.